Does the use of SGLT2 inhibitors reduce the risk of hyperkalemia in patients with diabetic kidney disease treated with RAAS inhibitors or MRAs?
SGLT2 inhibitors may protect against the hyperkalemia risk associated with MRAs and RAAS inhibitors in patients with diabetic kidney disease.
Among the therapeutic drugs with the potential risk of increasing serum potassium in patients with diabetic kidney disease, MRA added an extra risk of hyperkalemia while SGLT2i had the opposite effect and could even reverse the elevation of serum potassium caused by the combined regimen, including MRAs.
Luo et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: